biotech

From Analyst to CFO by Age 30: Michelle Gilson
Q&A

From Analyst to CFO by Age 30: Michelle Gilson

Arcellx’s Gilson is using her experience as a research analyst to succeed as a first-time CFO.
By Sandra Beckwith | September 8, 2022
Read More
uBiome Founders Charged With $60 Million Fraud
Supply Chain

uBiome Founders Charged With $60 Million Fraud

The SEC says Jessica Richman and Zachary Apte misrepresented that their biotech startup was generating reliable revenue from insurance reimbursements.
By Matthew Heller | March 19, 2021
Read More
Merck Buys OncoImmune in COVID Treatment Move
M&A

Merck Buys OncoImmune in COVID Treatment Move

The $425 million deal gives Merck access to a promising therapy for treating seriously ill COVID-19 patients.
By Matthew Heller | November 23, 2020
Read More
Moderna Q3 Revenues Beat Estimates
Financial Performance

Moderna Q3 Revenues Beat Estimates

The biotech is preparing for the global launch of its potential COVID-19 vaccine.
By Lauren Muskett | October 29, 2020
Read More
Bayer to Buy Gene Therapy Company AskBio
M&A

Bayer to Buy Gene Therapy Company AskBio

The pharma giant could pay as much as $4 billion if performance targets are met.
By Lauren Muskett | October 26, 2020
Read More
Biotech Exec Charged With COVID Test Fraud
Risk & Compliance

Biotech Exec Charged With COVID Test Fraud

The SEC says Arrayit President Mark Schena falsely claimed the company had developed a test and it was awaiting emergency FDA approval.
By Matthew Heller | September 28, 2020
Read More
Illumina Buys Cancer Test Startup Grail for $8B
M&A

Illumina Buys Cancer Test Startup Grail for $8B

The deal will move Illumina “deeper into the application of its gene-sequencing technology to the diagnosis and treatment of patients."
By Matthew Heller | September 21, 2020
Read More
Alexion Fined $21M in Foreign Corruption Probe
Risk & Compliance

Alexion Fined $21M in Foreign Corruption Probe

The SEC says the biotech firm made improper payments to Turkish and Russian officials to secure favorable treatment for its main drug.
By Matthew Heller | July 3, 2020
Read More
Moderna Stock Soars on COVID Vaccine Results
Risk & Compliance

Moderna Stock Soars on COVID Vaccine Results

Interim data from a Phase 1 study showed Moderna's vaccine candidate stimulated an immune response against the virus in people.
By Matthew Heller | May 18, 2020
Read More
SEC Questions COVID Drug Claims of Biotechs
Risk & Compliance

SEC Questions COVID Drug Claims of Biotechs

The commission has halted trading in the shares of three companies that have said they are developing a drug candidate for treating COVID-19.
By Matthew Heller | May 5, 2020
Read More
Moderna Gets $483M to Fund Corona Vaccine
Risk & Compliance

Moderna Gets $483M to Fund Corona Vaccine

The grant from the U.S. government will boost Moderna's efforts to develop what is “among the most advanced coronavirus vaccine candidates.”
By Matthew Heller | April 17, 2020
Read More
Four Pillars of Successful Corporate Decision-Making
Strategy

Four Pillars of Successful Corporate Decision-Making

Here's how to shift the decision-making process from a misunderstood art toward a mainstream science.
By David Mellor | March 11, 2020
Read More
SEC Charges Former MiMedx Execs With Fraud
Risk & Compliance

SEC Charges Former MiMedx Execs With Fraud

The C-suite executives allegedly improperly recognized revenue from distributors with which MiMedx had secret side arrangements.
By Matthew Heller | November 27, 2019
Read More
Gilead to Invest $5B in Galapagos Partnership
Strategy

Gilead to Invest $5B in Galapagos Partnership

The deal expands Gilead's investment in the European biotech as it seeks to add assets to its drug portfolio.
By Matthew Heller | July 15, 2019
Read More
Insys Shares Dive on ‘Going Concern’ Doubts
Financial Reporting

Insys Shares Dive on ‘Going Concern’ Doubts

The opioid seller's auditor expressed "substantial doubt" about its ability to continue as a going concern.
By Matthew Heller | March 14, 2019
Read More
Next